Drugs / NasoShield
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04415749 | Jun 2020 → Mar 2021 | — | Altimmune, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03352466 | Jan 2018 → May 2019 | — | Altimmune, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2021-04-01 | Altimmune, Inc. | Results Altimmune Reports Data from its Phase 1b Clinical Trial of NasoShield™ altimmune.com ↗
Serum binding antibody responses to the protective antigen of Bacillus anthracis, the bacterium and causative agent of anthrax, were significantly greater than in the placebo arm. |
| 2018-08-31 | Altimmune, Inc. | Results Altimmune Announces Initial Single-Dose Data from Its NasoShield Phase 1 Study altimmune.com ↗
Based on initial data from the single-dose cohorts, NasoShield was safe and well-tolerated with no serious adverse events. |
| 2017-12-11 | Altimmune, Inc. | Regulatory Altimmune Submits Investigational New Drug Application for NasoShield in Preparation for its Phase 1 Trial altimmune.com ↗
Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced the Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for NasoShield, the Company’s next generation anthrax vaccine. |
| 2015-10-12 | Altimmune, Inc. | Results Altimmune Chief Scientific Officer to Present at Two Premier Vaccine Conferences altimmune.com ↗
Vaccination with NasoShield produced serum anti-PA83 and toxin neutralizing antibody (TNA) titers with earlier onset and greater stability as compared BioThrax. |
| 2015-09-01 | Altimmune, Inc. | Results Vaxin Changes Company Name to Altimmune altimmune.com ↗
In its latest success, the company demonstrated in pre-clinical studies that a single intranasal vaccination with its NasoShield™ anthrax vaccine was non-inferior to the protection conferred by two vaccinations of the currently licensed Anthrax Vaccine Absorbed (AVA; BioThrax®). |
All press releases naming this drug 10 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NasoShield | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04415749 ↗ |
| Modality | Vaccine | “NasoShield is an adenovirus-vectored anthrax vaccine.” NCT03352466 ↗ |
| Route | Intranasal | “1 intranasal dose of NasoShield” NCT03352466 ↗ |